Core Insights - The strategic cooperation agreement between Innovent Biologics and Jianzhijia was officially signed on January 5, 2026, marking a significant partnership aimed at enhancing the distribution of innovative pharmaceuticals [1][2] - Innovent Biologics has achieved notable success in collaboration with Jianzhijia in 2025, particularly with the positive market feedback for its product, Sinleukin (Mastuzumab Injection), within Jianzhijia's retail network [1] - Jianzhijia aims to leverage its retail network and professional service capabilities to provide comprehensive health solutions by introducing high-quality drugs from innovative pharmaceutical companies like Innovent Biologics [1] Company Strategies - Innovent Biologics emphasizes the importance of retail channel development and plans to explore innovative drug development models in collaboration with Jianzhijia, focusing on patient education, pharmaceutical services, and medication tracking [2] - Jianzhijia's management has proposed specific collaboration directions, aiming to utilize its terminal network and professional service advantages for deeper cooperation in product promotion, patient management, and health services with Innovent Biologics [2]